AbstractBackground and purpose:
The long-acting muscarinic antagonist tiotropium received an indication for the treatment of asthma from the FDA in 2015.Methods:
This paper summarizes much of the published findings on tiotropium and asthma and explores the heterogeneity of the asthma population vis-à-vis recent changes in guidelines for management of COPD. The accompanying case study provides an illustration of how tiotropium might be added to a patient's regimen appropriately.Conclusions and implications for practice:
Tiotropium has been shown in many studies to be beneficial to patients with asthma as an add-on medication. It should be considered as an agent by the clinician managing patients with both allergic and non-allergic asthma.